SLC2A1 promotes chemo-immunotherapy resistance in lung adenocarcinoma by modulating the AKT signaling pathway
Chemo-immunotherapy has become a standard treatment for lung adenocarcinoma (LUAD), yet the development of dual resistance to platinum-based chemotherapy and PD-1/PD-L1 blockade severely limits durable clinical benefit. This study aimed to identify a unified molecular regulator that concurrently drives chemoresistance...